Experience with long-term use of epoetin alfa for the correction of anemia in patients on hemodialysis
- Authors: Pushkina A.V.1, Fesyuk A.A.1
-
Affiliations:
- OOO FESFARM COMPANY
- Issue: Vol 17, No 4 (2025)
- Pages: 5-9
- Section: Original Articles
- URL: https://ogarev-online.ru/2075-3594/article/view/375403
- DOI: https://doi.org/10.18565/nephrology.2025.4.5-9
- ID: 375403
Cite item
Open Access
Access granted
Subscription Access
Abstract
Objective. Evaluation of the efficacy of long-term use of epoetin alfa for the correction of anemia in patients on program hemodialysis (HD).
Material and Methods. A retrospective analysis of anemia treatment in patients on program HD was conducted. The study included patients treated with epoetin alfa in 0.25 ml syringes at a dose of 2500 IU.
Results. Over a 4-year follow-up period, mean hemoglobin, ferritin, and transferrin saturation levels increased statistically significantly, while the epoetin alfa dose and erythropoietin resistance index decreased statistically significantly.
Conclusion. The results of long-term use of epoetin alfa at a single dose of 2500 IU for the correction of anemia in dialysis patients demonstrated its high efficacy and safety. Maintaining optimal iron stores in the body is an important prerequisite for successful anemia correction.
Keywords
About the authors
Anna V. Pushkina
OOO FESFARM COMPANY
Author for correspondence.
Email: avpushkina@yandex.ru
ORCID iD: 0000-0003-1560-7289
Chief Physician
Russian Federation, MoscowAnna A. Fesyuk
OOO FESFARM COMPANY
Email: faa001@mail.ru
ORCID iD: 0009-0000-2714-0271
Deputy General Director for Medical Affairs
Russian Federation, MoscowReferences
- Kidney Disease Improving Global Outcomes KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int. Suppl. 2012;2:279–335.
- Hanna R.M., Streja E., Kalantar-Zadeh K. Burden of Anemia in Chronic Kidney Disease: Beyond Erythropoietin. Adv. Ther. 2021;38(1):52–75.
- Palaka E., Grandy S., van Haalen H. et al. The Impact of CKD Anaemia on Patients: Incidence, Risk Factors, and Clinical Outcomes-A Systematic Literature Review. Int. J. Nephrol. 2020;2020:769237. doi: 10.1155/2020/7692376. eCollection 2020.
- Pfeffer M.A., Burdmann E.A., Chen C.Y. et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N. Engl. J. Med. 2009;361(21):2019–32.
- Drüeke T.B., Locatelli F., Clyne N. et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. . N. Engl. J. Med. 2006;355(20):2071–84.
- Singh A.K., Szczech L., Tang K.L. et al. Correction of anemia with epoetin alfa in chronic kidney disease. N. Engl. J. Med. 2006;355(20):2085–98.
- Клинические рекомендации «Анемия при хронической болезни почек». http: cr.minzdrav.gov.ru. [Clinical guidelines «Anemia in Chronic Kidney Disease». http: cr.minzdrav.gov.ru. (In Russ.)].
- Chung E.Y., Palmer S.C., Saglimbene V.M. et al. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis. Cochrane Database Syst. Rev. 2023;2(2):CD010590. doi: 10.1002/14651858.CD010590.pub3.
- Клинические рекомендации «Хроническая болезнь почек (ХБП)», 2021. http: cr.minzdrav.gov.ru. [Clinical Guidelines «Chronic Kidney Disease (CKD)», 2021. http: cr.minzdrav.gov.ru (In Russ.)].
- Okazaki M., Komatsu M., Kawaguchi H. et al. Erythropoietin resistance index and the all-cause mortality of chronic hemodialysis patients. Вlood Purif. 2014;37(2):106–12.
- Jovana Joksimovic Jovic, Antic S., Nikolic T. et al. Erythropoietin Resistance Development in Hemodialysis Patients: The Role of Oxidative Stress. Oxid. Med. Cell Longev. 2022;:2022:9598211.
- Locatelli F., Covic A., Eckardt K.U. et al. ERA-EDTA ERBP Advisory Board: Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). Nephrol. Dial. Transplant. 2009;24:348–54.
- DOPPS practice monitor-hemodialysis www. dopps.org.
- Wish J.B., Rocha M.G., Martin N.E. et al., Long-term Safety of Epoetin Alfa-epbx for the Treatment of Anemia in ESKD: Pooled Analyses of Randomized and Open-label Studies. Kidney Med. 2019;1(5):271–80.
- Kawai T., Kusano Y., Yamada K. et al. Long-term maintenance of hemoglobin levels in hemodialysis patients treated with bi-weekly epoetin beta pegol switched from darbepoetin alfa: a single-center, 12-month observational study in Japan. J. Artif. Organs. 2019;22(2):146–53.
- Del Vecchio L., Locatelli F. An overview on safety issues related to erythropoiesis-stimulating agents for the treatment of anaemia in patients with chronic kidney disease. Expert. Opin. Drug Saf. 2016;15:1021–30.
- Lim S.K., Goh B.L., Visvanthan R. et al. A multicentre, multi-national, double-blind, randomised, active-controlled, parallel-group clinical study to assess the safety and efficacy of PDA10 (Epoetin-Alfa) vs. Eprex® in patients with anaemia of chronic renal failure. BMC. Nephrol. 2021;22(1):391. doi: 10.1186/s12882-021-02601-w.
Supplementary files
